Results 221 to 230 of about 968,831 (312)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Evaluation of the impact of student-led clinics on medical students' knowledge, skills, and professional growth. [PDF]

BMC Med Educ
Abidi SMA, Fatima SK, Lodhi BA, Nazeer AH, Ali SMF, Rizvi MMH.   +5 more
europepmc   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Importance of Application-Specific Testing for Vitamin A in Food Fortification

Current Developments in Nutrition
Haisong Yang, Samantha Brady, Justyna Ebbensen, Elise Ivarsen, Donald Chickering, Julie Straub   +5 more
doaj   +1 more source

Consulting AI: building inclusiveness in acute care surgery. [PDF]

Trauma Surg Acute Care Open
Rowan A.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Ritual's collective effervescence, awe, and social identity: psychosocial effects of the Pasto carnival. [PDF]

Front Psychol
Rincón-Unigarro C, da Costa-Dutra S, Cisneros-Rodríguez MJ, Díaz-Fuentes L, Giraldo-Castillo N, Murcia-Infante A, Páez D, Vargas-López M, Vásquez-Velásquez S.   +8 more
europepmc   +1 more source

Common Humanity [PDF]

, 1974
Lancaster, Beverly
core  

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

The Invisible Hand, the Visible Wound, and the Commercial Determinants of Health: Complicity of Commercial Entities and the Palestine Catastrophe. [PDF]

Int J Soc Determinants Health Health Serv
Mofizul Islam M.
europepmc   +1 more source